| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
N-Acetyldopamine dimer-1 does not have a well-defined pharmacological target in the literature. As a natural product derived from N-acetyldopamine, it may interact with pathways related to dopamine metabolism or melanin biosynthesis. N-acetyldopamine derivatives are known to be involved in insect cuticle sclerotization and pigmentation. The compound may also have antioxidant or enzyme inhibitory activities, but specific targets have not been extensively characterized. Further research is needed to identify its molecular targets.
|
|---|---|
| ln Vitro |
In vitro activity of N-Acetyldopamine dimer-1 has not been extensively reported in the scientific literature. As a natural product from cicada shells, it may exhibit antioxidant properties due to its catechol (dihydroxyphenyl) structure, which is known to scavenge free radicals. It may also show enzyme inhibitory activities, particularly against enzymes involved in melanin biosynthesis such as tyrosinase. However, quantitative in vitro activity data (e.g., IC50 values) are not readily available from publicly accessible sources.
|
| ln Vivo |
N-Acetyldopamine dimer-1 has not been reported to have significant in vivo pharmacological activity. As a natural product isolated from cicada shells, it may have been used in traditional medicine contexts, but modern pharmacological studies are limited. The compound's in vivo effects, if any, would likely relate to its antioxidant properties or potential interactions with dopaminergic systems. No specific in vivo efficacy data are available from the literature.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for N-Acetyldopamine dimer-1 would typically involve screening against a panel of enzymes or receptors to identify potential targets. Given its structural similarity to catechol-containing compounds, assays for tyrosinase inhibition, monoamine oxidase inhibition, or antioxidant activity (DPPH radical scavenging) would be appropriate. Binding to dopamine receptors or other catecholamine-related targets could also be assessed using radioligand binding assays. However, specific published protocols for this compound are not available.
|
| Cell Assay |
In vitro cell-based assays for N-Acetyldopamine dimer-1 would involve culturing appropriate cell lines (e.g., melanocytes, neuronal cells) and treating them with the compound to assess effects on cell viability, melanin production, or oxidative stress. Cytotoxicity would be evaluated using MTT or LDH release assays. Antioxidant activity could be assessed by measuring reactive oxygen species (ROS) levels using fluorescent probes such as DCFH-DA. Specific protocols would need to be developed based on the research question and are not available in the public literature.
|
| Animal Protocol |
In vivo animal studies for N-Acetyldopamine dimer-1 have not been reported in the literature. As a natural product from cicada shells, it may have been used in traditional medicine, but modern pharmacological studies in animal models are lacking. If conducted, such studies might involve oral or intraperitoneal administration in rodents to assess pharmacokinetics, toxicity, or efficacy in models of oxidative stress or neurodegenerative diseases.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of N-Acetyldopamine dimer-1 have not been characterized. As a small molecule with a molecular weight of 386.40 and multiple hydroxyl groups, it is expected to have moderate aqueous solubility and may undergo extensive first-pass metabolism. The compound may be absorbed orally, but bioavailability would depend on its stability in the gastrointestinal tract and hepatic metabolism. No specific PK parameters such as half-life, Cmax, or bioavailability are available.
|
| Toxicity/Toxicokinetics |
The toxicity profile of N-Acetyldopamine dimer-1 has not been systematically evaluated. As a natural product, it may have a favorable safety profile, but this has not been confirmed in controlled toxicology studies. The presence of catechol groups suggests potential for oxidative stress at high concentrations, which could lead to cytotoxicity. Standard toxicity assessments would include acute and sub-chronic dosing in rodents, with endpoints including clinical signs, body weight, clinical pathology, and histopathology. No toxicity data are available.
|
| References |
[1]. Noda N, et al. Optically active N-acetyldopamine dimer of the crude drug "Zentai," the cast-off shell of the Cicada, Cryptotympana sp. Chem Pharm Bull (Tokyo). 2000 Nov;48(11):1749-52.
|
| Additional Infomation |
N-Acetyldopamine dimer-1 is a natural product of research interest, isolated from the cicada shell "Zentai". It is an optically active 2-(3',4'-dihydroxyphenyl)-1,4-benzodioxane derivative. The compound has a molecular formula of C20H22N2O6 and a molecular weight of 386.40. It is not approved for clinical use and is available only for research purposes. Further studies are needed to elucidate its biological activities and potential pharmacological applications.
|
| Molecular Formula |
C20H22N2O6
|
|---|---|
| Molecular Weight |
386.40
|
| Exact Mass |
386.147
|
| CAS # |
315188-82-0
|
| PubChem CID |
10643865
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
1.5
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
28
|
| Complexity |
559
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
CC(=O)NCCC1=CC2=C(C=C1)O[C@@H]([C@H](O2)C3=CC(=C(C=C3)O)O)NC(=O)C
|
| InChi Key |
MXCCEJSRHCXZMV-UXHICEINSA-N
|
| InChi Code |
InChI=1S/C20H22N2O6/c1-11(23)21-8-7-13-3-6-17-18(9-13)27-19(20(28-17)22-12(2)24)14-4-5-15(25)16(26)10-14/h3-6,9-10,19-20,25-26H,7-8H2,1-2H3,(H,21,23)(H,22,24)/t19-,20+/m1/s1
|
| Chemical Name |
N-[2-[(2S,3R)-2-acetamido-3-(3,4-dihydroxyphenyl)-2,3-dihydro-1,4-benzodioxin-6-yl]ethyl]acetamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5880 mL | 12.9400 mL | 25.8799 mL | |
| 5 mM | 0.5176 mL | 2.5880 mL | 5.1760 mL | |
| 10 mM | 0.2588 mL | 1.2940 mL | 2.5880 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
